Entity family
Named questionnaires, scales, scores, indices, and other clinical outcome assessments. Examples include PHQ-9, GAD-7, EQ-5D.
This clinical instrument is selected. Its supporting articles are shown below.
…ulticenter Phase 2a trial enrolled patients aged ≥18 years with ECOG performance status 0 or 1 and measurable disease. Eligible patients had either ant…
…teria are 1) histologically or pathologically confirmed HCC; 2) ECOG performance status of 0 or 1 with life expectancy > 12 weeks; 3) Child-Pugh class …
…ing to RECIST 1.1 criteria. Enrolled patients must also have an Eastern Cooperative Oncology Group performance status of 0 or 1. Eligible patients received tislelizumab (200 mg, IV …
…r free flap reconstruction, be checkpoint inhibitor naïve, with ECOG performance status of <2. Key exclusion criteria include recent radiation therapy …
…moking status, socioeconomic status, practice type and baseline ECOG performance status. Overall survival (OS) was compared between the B cell deficien…
…1-1.02, p = .1512). After controlling for covariables including ECOG performance status, histology, concurrent therapies, metastases, and comorbidities…
…eatment (surgery, radiotherapy, chemotherapy), cancer stage and ECOG performance status.2. 28 from the 194 smokers (15%) became long-term quitters. The…
…of 0.72 (95% CI: 0.65 to 0.78) for 5-year survival, identifying Eastern Cooperative Oncology Group Performance Status (ECOG-PS)≥2, increasing age, and metastatic burden as primary r…
…n).Results All patients received ipilimumab plus nivolumab. The Eastern Cooperative Oncology Group performance status was 0 in 75.0% of patients, and nearly all (27/28) developed se…
…ignant bowel obstruction was the main indication for HPN (86%). Eastern Cooperative Oncology Group performance status (PS) scores were ≤2 in 82% of patients and 75% had an estimated…
…ceived previous systemic treatment, had measurable disease, and Eastern Cooperative Oncology Group performance status 0–1. Retifanlimab 500 mg was administered intravenously every 4…
…r (AJCC) staging system and WHO type II or III disease, with an Eastern Cooperative Oncology Group performance status of 0–1, satisfactory liver and renal functions, complete treatm…